Pharmaceuticals
Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer
SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...
2023-08-11 17:00
3941
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 11:14
1994
WuXi XDC and Boostimmune Sign MOU for Integrated Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating ...
2023-08-11 08:30
1599
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland ofChina - Antengene to receive up to RMB200 million in upfront payments,...
2023-08-11 08:00
2870
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 07:18
2046
YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023
GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-08-11 04:30
4856
Standigm and Nashville Biosciences join to revolutionize early drug discovery
Companies will identify novel therapeutic targets using Standigm's explainable
AI and Nashville Biosciences' datasets
SEOUL, South Korea, Aug. 10, 2023 /PRNewswire/ -- Standigm
2023-08-10 21:07
1498
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed...
2023-08-10 21:00
2262
AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge (primary endpoint, p...
2023-08-10 15:49
4471
Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]
* First pneumococcal conjugate vaccine that fights against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia[2],[3] — one of the leading causes of death inHong Kong[4] — has been approved by Hong Kong Department of Health inApril 2023 and is now available in Hong ...
2023-08-10 14:15
1857
![Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]](https://mma.prnasia.com/media2/2155046/Pfizer.jpg?p=medium600)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Aug. 9, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that...
2023-08-09 13:00
2871
Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023
SHANGHAI, Aug. 9, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the fir...
2023-08-09 08:06
2199
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis
HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of atopic dermatitis. The study was...
2023-08-09 08:00
3056
Race Strategic Update August 2023
SYDNEY, Aug. 9, 2023 /PRNewswire/ -- Race Oncology Limited ("Race") is pleased to provide a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene's commercial partnering and collaboration potential. Ev...
2023-08-09 07:30
2864
Neuragenex Expands to Open New Illinois Location, Giving More People Access to its Innovative Approach to Chronic Pain Management
CHICAGO, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of four new locations inIllinois. With its groundbreaking approach to chronic pain management that is drug-free and non-in...
2023-08-09 00:14
1310
Neuragenex Expands to Open New Georgia Locations, Giving More People Access to its Innovative Approach to Chronic Pain Management
ATLANTA, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of theLawrenceville clinic location in Georgia. With its groundbreaking approach to chronic pain management that is drug-fr...
2023-08-09 00:13
1339
Neuragenex Expands to Open New Utah Location, Giving More People Access to its Innovative Approach to Chronic Pain Management
SALT LAKE CITY, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening ofBluffdale and Lehi clinic locations in Utah. With its groundbreaking approach to chronic pain management that is d...
2023-08-09 00:13
1372
Neuragenex Expands to Open New Texas Location, Giving More People Access to its Innovative Approach to Chronic Pain Management
VICTORIA and WACO, Texas, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of theWaco and Victoria clinic locations inTexas. With its groundbreaking approach to chronic pain managem...
2023-08-09 00:03
1380
Vatech Announces Distribution Through Henry Schein to Help Oral Health Professionals Enhance Access to Cutting-Edge Imaging Solutions
HWASEONG, South Korea, Aug. 8, 2023 /PRNewswire/ -- Vatech, a global leader in the dental imaging market, has announced that its products will be distributed byHenry Schein, helping to expand the availability of its cutting-edge products for dental clinics inNorth America. Vatech's portfolio o...
2023-08-08 21:00
1707
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updat...
2023-08-08 20:00
1668
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 274 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
14100
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
10196
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8408
